Clinical Response of Abnormal Endometrial Growth to Hormonal Treatment

Annals of the New York Academy of Sciences

Volumn 734, Issue 1, 1994, Pages 306-309

  GONZÁLEZ, E LÓPEZ DE LA OSA ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; TAMOXIFEN; TRIPTORELIN;

BREAST CANCER; CONFERENCE PAPER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONAL THERAPY; HUMAN;

EID: 0028609777     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1994.tb21760.x     Document Type: Article

References (13)

1. The role of progesterone in human endometrial cancer.
2. Estradiol and 20α dihydroprogesterone dehydrogenase activities in human endometrium during the menstrual cycle.
3. The histochemistry of oestradiol 17β and isocitric dehydrogenases in endometrial carcinoma.
4. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer.
5. Effect of a systemically administered progesterone on the istopathology of endometrial carcinoma.
6. Progesterone receptors in two groups of endometrial adenocarcinoma.
7. Effects of hormone therapy on the endometrium.
8. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.
9. Tamoxifen associated endometrial carcinoma in postmenopausal breast cancer patients.
10. Tamoxifen and endometrial neoplasia: a report of eleven cases.
11. Stimulatory effects of 4‐hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line)
12. Tamoxifen for breast cancer: associated endometrial cancer.
13. A new treatment for endometrial cancer with gonadotrophin releasing‐hormone analog.